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Hepatitis B and Hepatitis B Vaccine
Disease
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Hepadnaviridae family (DNA)
Numerous antigenic components
May retain infectivity for more than   
7 days at room temperature
Hepatitis B Virus
Hepatitis B Virus Infection
786,000
deaths 
worldwide 
850,000–
2.2 million
US chronic 
infections
257 million
chronic infections 
worldwide 
Causes
50%
of hepatocellular 
carcinomas
https://www.cdc.gov/hepatitis/hbv/bfaq.htm#bFAQb04
 Reservoir Human
 Transmission percutaneous (i.e., puncture 
through the skin) or mucosal contact 
with infectious blood or body fluids 
(e.g., semen, saliva)
 Communicability 1-2 months before and after onset 
of symptoms
Persons with either acute or chronic 
HBV infection with HBsAg present in 
blood
Hepatitis B Epidemiology
Incubation period 60-150 days (average 90 days)
Nonspecific prodrome of malaise, fever, headache, myalgia
Children < 5 years and newly infected immunosuppressed adults 
generally asymptomatic
• 30%–50% of persons aged ≥5 years have signs and symptoms
Hepatitis B Clinical Features 
Fulminant hepatitis (<1%)
Hospitalization
Cirrhosis
Hepatocellular carcinoma
Death
Hepatitis B Complications
Injection drug use
2 or more sexual partners
Men who have sex with men
Household contacts of persons 
with HBV
Developmentally disabled 
persons in long-term-care 
facilities
Correctional facilities
Persons at risk for occupational 
exposure to HBV
Hemodialysis patients
Persons with HCV infection
Persons with chronic liver disease
Travelers to countries where HBV 
is endemic
Persons with HIV 
Persons with Diabetes
Risk Factors for Hepatitis B

80-90% of persons infected during infancy
30% of persons infected before age 6 years
1-12% of persons infected as an older child or adult
Approximately 25% of persons chronically infected during 
childhood and 15% chronically infected after childhood will die 
prematurely from cirrhosis or liver cancer
Chronic Hepatitis B Virus Infection
Risk of Chronic HBV Infection
J Hepatol. 2008;48(2):335-52
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Immune tolerant
• Minimal or no hepatic inflammation or fibrosis
Immune active
• Hepatic inflammation with or without fibrosis
Immune inactive
• Improvement of hepatic inflammation and fibrosis
Reactivation
• Active hepatic inflammation with or without fibrosis
Chronic Hepatitis B Virus Infection – 4 Phases
Hepatitis B Perinatal Transmission*
*in the absence of post exposure prophylaxis 
HBsAg+ & 
HBeAg+
HBsAg+ only
70-90% 
infected
10% 
infected
Up to 90% of
infected infants 
become 
chronically 
infected
Prevent perinatal HBV transmission
• Routine testing of all pregnant women for HBsAg
oProphylaxis (HepB vaccine and HBIG) for infants born to HepB surface antigen 
(HBsAg) positive women
oHBV DNA testing for HBsAg positive women and antiviral therapy if HBV DNA is 
>200,000 IU/mL
Universal vaccination of all infants at birth
Routine vaccination of previously unvaccinated children and 
adolescent (<19 years of age)
Vaccination of adults  at risk for HBV infection
Strategy to Eliminate Hepatitis B Virus Transmission—
United States
https://www.cdc.gov/mmwr/volumes/67/rr/rr6701a1.htm#B2_down
New!
Vaccine
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Hepatitis B-Containing Vaccine Products*
*ACIP does not state a preference for vaccine product versus another if the patient is eligible for more than 1 product 
Vaccine product Age indications
Single-component vaccines
Engerix-B
Pediatric formulation Birth–19 years
Adult formulation 20 years and older
Recombivax HB
Pediatric formulation Birth–19 years
Adult formulation 20 years and older
Heplisav-B 18 years and older
Combination vaccines
Pediarix–DTaP, IPV and HepB vaccines 6 weeks–6 years
Twinrix–HepA and HepB vaccines 18 years and older
Recombivax HB
Dose (mcg)
Engerix-B*
Dose (mcg)
Heplisav-B
Dose (mcg)
Children: Birth through 19 years 0.5 mL (5) 0.5 mL (10) N/A: <17 yrs0.5 mL (20): >18 yrs
Adults: 20 years and older 1.0 mL (10) 1.0 mL (20) 0.5 mL (20)
Recommended Dosage of HepB Vaccine
*Pediarix contains the pediatric formulation of Engerix-B
*Twinrix contains the adult formulation of Engerix-B
† Heplisav-B approved for use in persons 18 years of age or older
Recombivax HB
Dose (mcg)
Engerix-B*
Dose (mcg)
Heplisav-B
Dose (mcg)
Composition Recombinant HBsAg Recombinant HBsAg AdjuvantedRecombinant HBsAg
Efficacy 95% 
(Range, 80%–100%)
95% 
(Range, 80%–100%) 90%–100%
Schedule 3 doses 3 doses 2 doses
Route IM IM IM
HepB Vaccine
*Pediarix contains the pediatric formulation of Engerix-B
*Twinrix contains the adult formulation of Engerix-B 
Pediarix DTaP/IPV/HepB
• Ages: 6 weeks through 6 years
• Routine schedule: 2, 4, 6 months of age
• Approved for dose 1, 2, 3 of Hep B (Do NOT use for the birth dose) 
Twinrix HepA/HepB
• Ages: 18 years of age and older   
• Routine schedule:3 doses at 0, 1, 6 months, or
• 0, 7, 21- 30 days and a booster dose at 12 months
• Each dose of Twinrix contains an adult dose of hepatitis B vaccine
• A HepB series started with Twinrix can be complete with single antigen 
HepB vaccine and vice versa
Combination Vaccines 
Clinical 
Considerations
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Routinely recommended for all children birth through 18 years 
of age
Vaccinate previously unvaccinated children and those missing 
doses 
ACIP HepB Vaccine Recommendations: Pediatric  
Dose+ Routine Age    
Dose 1 Birth§
Dose 2 1- 2 months
Dose 3+ 6-18 months*
HepB Schedule: Routine Infant 
§The birth dose of single-component Hepatitis B vaccine should be administered within 24 hours of birth for medically stable infants weighing ≥2,000 
grams born to hepatitis B surface antigen (HBsAg)-negative mothers.
*Infants whose mothers are HBsAg+ or whose HBsAg status is unknown should receive the third dose at 6 months of age
+An additional dose at 4 months is acceptable if the clinician prefers to use a combination vaccine that contains hepatitis B vaccine
HepB Schedule: Minimum Age and Intervals 
4-day grace can be applied to minimum age and intervals 
16 weeks
1 2 3DOSE DOSE DOSE
4 weeks 8 weeks
6 months = 
minimum age
Can be given to infants who received HepB at birth = 4 doses*
Do NOT use for the birth dose
Pediarix Schedule Considerations 
*An additional dose at 4 months is acceptable if the clinician prefers to use a combination vaccine that contains hepatitis B vaccine 
1DOSE
Birth
Engerix B or 
Recombivax HB
DOSE2
2 months
Pediarix
DOSE3
4 months
Pediarix
DOSE4
6 months is the minimum 
age for the last dose 
6 months
Pediarix
Birth Dose Considerations: 
Babies Weighing 2000 grams or more 
*Administer HepB vaccine and HBIG in separate limbs  
Administer HepB
vaccine within 
24 hours of birth  
HBsAg NEGATIVE
mother 
HBsAg POSITIVE
mother 
HBsAg UNKNOWN
mother 
Administer HepB
vaccine and HBIG* 
within 12 hours of birth  
Administer HepB
vaccine within 12 hours 
of birth and test to 
determine mother’s 
status ASAP 
Birth Dose Considerations: 
Babies Weighing Less Than 2000 grams 
*Administer HepB vaccine and HBIG in separate limbs  
Administer HepB
vaccine at hospital 
discharge or at 1 
month of age  
HBsAg NEGATIVE
mother 
HBsAg POSITIVE
mother 
HBsAg UNKNOWN
mother 
Administer HepB vaccine 
and HBIG* within 
12 hours of birth  
Administer HepB vaccine  
within 12 hours of birth. 
Give HBIG, if the mother’s 
HBsAg status cannot be 
determined within 12 hours 
of birth* 
Administer HepB vaccine and HBIG within 12 hours of birth
• HepB vaccine and HBIG can be administered at the same time 
• HepB and HBIG are both IM injections 
• Administer in different limbs
Complete vaccination series at 6 months of age
• 1st dose does not count when administered to infants weighing less 
than 2000 grams 
Test for response after completing a 3-dose series at 9 through 
12 months of age
Medical Considerations: Treating Infants Whose Mother 
is Hepatitis B Surface Antigen POSITIVE
Infants born to women without HBsAg testing results but 
other evidence suggests maternal HBV infection exists, 
administer both HepB and HBIG within 12 hours of birth
Test mother for HBsAG status as soon as possible 
• Infants weighing 2000 grams or more: If mother is determined to be 
hepatitis B surface antigen positive give HBIG as soon as possible, but 
no later than age 7 days
• Infants weighing less than 2000 grams: If the mother tests positive or 
HBsAG status can not be determined, administer HBIG within 12 hours 
of birth    
Medical Considerations: Treating Infants Whose Mother is 
Hepatitis B Surface Antigen UNKNOWN
Prevaccination serologic testing is: 
• Not indicated before routine vaccination of infants or children
• Recommended for all persons born in Africa, Asia, the Pacific Islands, 
and other regions with HBsAg prevalence of 2% or higher
Postvaccination serologic testing is: 
• Not routinely recommended following vaccination of infants, children, 
and adolescents 
• Recommended for infants born to HBsAg+ women
Serologic Testing and Children 
 Vaccination recommended unvaccinated adults at risk for 
HBV infection and adults requesting protection from HBV 
infection 
• Acknowledgement of a specific risk factor not required vaccination
ACIP HepB Vaccine Recommendations: Adult
Hepatitis C virus infection
Chronic liver disease
HIV infection
Sexual exposure risk
Adults at Risk for HBV Infection
* Persons with more than one sex partner during the previous 6 months 
Current or recent injection drug use
Percutaneous or mucosal risk for exposure to blood
Incarcerated persons
Travel in countries with high or intermediate endemic hepatitis B
Adults at Risk for HBV Infection
* Persons with more than one sex partner during the previous 6 months 
Dose RoutineInterval Minimum Interval
Dose 1 --- ---
Dose 2 1 month 4 weeks
Dose 3 6 months 8 weeks and at least 16 weeks from Dose 1
HepB Schedule: Adult
Recombivax HB or Engerix-B 
Storage Store in the refrigerator between 
2°C and 8°C (36°F and 46°F)
Ages 18 years of age and older 
Schedule Administer 2 doses separated by 4 weeks 
Administration Intramuscular (IM) injection in the deltoid
Can be administered at the same clinical visit as other 
vaccines. Administer in separate injection sites, 1 inch 
apart (if possible)
Contraindication History of severe allergic reaction (e.g., anaphylaxis) after a 
previous dose of any hepatitis B vaccine or to any 
component of Heplisav-B, including yeast
Heplisav-B (HepB-CpG)
Heplisav-B package insert. Accessed 4/2018 
2-dose HepB series only applies when BOTH doses are 
Heplisav-B, administered at least 4 weeks apart 
• Any 2 doses of Heplisav-B separated by 4 weeks is considered complete, 
even if the patient has had other HepB vaccine products
Until safety data are available for Heplisav-B, providers should 
vaccinate pregnant women needing HepB vaccination with 
Engerix-B or Recombivax HB
Additional Heplisav-B Considerations 
MMWR 2018;(No.15):455–58 
Scenarios   
1.
HepB
Engerix-B or RecombivaxHB
01/01/2018 
HepB-CpG
Heplisav-B
02/01/2018 
HepB-CpG
Heplislav-B
03/01/2018
Completed series 
No additional doses 
are needed 
2.
HepB
Engerix-B or RecombivaxHB
01/01/2018  
HepB
Engerix-B or RecombivaxHB
05/01/2018
HepB-CpG
Heplisav-B
02/01/2018
Completed series 
No additional doses 
are needed 
Compared with adults without diabetes, adults with diabetes 
have a 60% higher prevalence of past or present HBV infection 
and twice the odds of acquiring acute HBV
• Possibility of a higher case-fatality proportion among persons with 
diabetes acutely infected with HBV 
ACIP recommends HepB vaccination for persons with diabetes 
mellitus aged <60 years and persons with diabetes mellitus 
aged ≥60 years at the discretion of the treating clinician
• No preference for any of the available vaccines
Diabetes Mellitus
MMWR Recomm Rep 2018;67(No. RR-#):[1-31]
Hepatitis B vaccination is recommended for susceptible 
hemodialysis patients
Hepatitis B vaccine is also indicated for patients whose renal 
disease is likely to lead to dialysis or transplantation
Dialysis 
MMWR Recomm Rep 2018;67(No. RR-#):[1-31]
For patients undergoing hemodialysis and for other 
immunosuppressed patients, higher vaccine doses or 
increased number of doses are required
• Special formulations of the vaccines are now available for such persons 
(Recombivax HB, 40 µg/mL, Energix_B, 40 µg/mL)
If an adult patient begins the vaccine series with a standard 
dose before beginning hemodialysis treatment, then moves to 
hemodialysis treatment before completing the series, 
complete the series using the higher dose recommended for 
hemodialysis patients
Dialysis
ACIP HepB Vaccine Recommendations: Healthcare and Public 
Safety Personnel
All healthcare personnel (HCP) whose 
work-, training-, and volunteer-related 
activities involve reasonably anticipated 
risk for exposure to blood or body fluids 
should be assessed for evidence of 
immunity to hepatitis B. 
Written documentation of a complete HepB vaccine series
AND
Subsequent documented anti-HBs ≥10 mIU/mL
Evidence of Immunity for HCP = 
Documentation of complete series AND documented positive titer
Unvaccinated (or incomplete series)
Documentation of complete series but no documented positive titer
Common Clinical Scenarios for HCP 
HCP considered immune
NO additional serologic testing or vaccine “booster” doses 
Advise the person to keep a copy of the vaccine record and 
positive titer FOREVER
Documentation of complete vaccine series AND documented 
positive titer
Vaccinate 
Unvaccinated HCP (or incomplete vaccine series)
Post-vaccination 
serologic testing 
(1-2 months after 
final dose)
Positive 
(anti-HBs ≥10 
mIU/mL) 
HCP considered 
immune
No further serologic 
testing or vaccination 
recommended
Negative 
(anti-HBs <10 
mIU/mL) 
Administer a second 
complete HepB
vaccine series
Post –vaccination 
serologic testing 
(1-2 months after 
final dose)
Documentation of complete vaccine series but no documented 
positive titer 
Serologic testing
Positive 
(anti-HBs ≥10 
mIU/mL) 
HCP considered 
immune
No further serologic 
testing or vaccination 
recommended
Serologic testing
Negative 
(anti-HBs <10 
mIU/mL) 
Documentation of complete vaccine series but no documented 
positive titer (2)
Administer 1 dose of 
HepB vaccine
Followed by post-
vaccination serologic 
testing 
(1-2 months later)
Positive 
(anti-HBs ≥10 
mIU/mL) 
HCP considered 
immune
No further serologic 
testing or vaccination 
recommended
Negative 
(anti-HBs <10 
mIU/mL) 
Complete second 
HepB vaccine series
Post –vaccination 
serologic testing 
(1-2 months after 
final dose)
Less than 5% of vaccinees do not develop anti-HBs after 6 valid 
doses
May be nonresponder or “hyporesponder”
Check HBsAg status 
If exposed, treat as nonresponder with postexposure
prophylaxis
Persistent Nonresponse to HepB Vaccine
HCP and Postexposure Management 
https://www.cdc.gov/mmwr/volumes/67/rr/pdfs/rr6701-H.pdf
Recommended for:
• All persons born in Africa, Asia, the Pacific Islands, and other regions 
with HBsAg prevalence of 2% or higher
• Household, sex, and needle-sharing contacts of HBsAg-positive persons
• Men who have sex with men
• Injection drug users
• Certain persons receiving cytotoxic or immunosuppressive therapy
Prevaccination Serologic Testing
Serologic testing is NOT routinely recommended following 
vaccination of most persons
Recommended for:
• Chronic hemodialysis patients
• Other immunocompromised persons
• Persons with HIV infection
• Sex partners of HBsAg+ persons
• Health care personnel
Postvaccination Serologic Testing
Revaccination is generally not recommended for persons with 
a normal immune status
Recommended for the following:
• HBsAg-negative infants with anti-HBs <10 mIU/mL (born to HBsAg-
positive mothers)
• Hemodialysis patients
• HIV-infected persons
• Other immunocompromised persons
Revaccination
Route: IM Injection 
• Needle gauge: 22–25 gauge
• Needle length*: 5/8 – 1.5 inch depending on the patient’s age and/or 
weight 
Site*: 
• Birth–11 months: Vastus lateralis muscle is preferred
• 1–3 years:  Vastus lateralis muscle is preferred; deltoid muscle may be 
used if the muscle mass is adequate 
• 4 years and older: Deltoid muscle is preferred; vastus lateralis muscle 
may be used
Vaccine Administration 
*Professional judgement should be used to determine the proper needle length and site.  Factors influencing site including local reaction, number of vaccine to be administered age and muscle mass
Route: IM Injection
• Administer HepB vaccine and HBIG (if needed) in different limbs
Site: NO BUTTS!
Vaccine Administration Considerations
Administration Errors Count the Dose or Revaccinate?
Adult formulation administered to a child Count the dose, if it meets minimum age and 
interval
Pediatric formulation administered to an 
adult
Dose does not count and should be repeated 
ASAP 
HepA instead of HepB vaccine Administer HepB vaccine ASAP
Contraindication
• Severe allergic reaction to a vaccine component or following a prior 
dose
Precaution
• Moderate or severe acute illness
HepB Vaccine Contraindications and Precautions
Symptom Frequency
Pain at injection site 3%-29%
Erythema 3%
Swelling 3%
Fever 1%-6%
Headache 3%
Severe systemic reactions rare
HepB Vaccine Adverse Reactions
Store HepB-containing vaccines in a 
refrigerator between 2°C - 8°C       (36°F -
46°F) 
DO NOT FREEZE 
Store in the original packaging with the 
lids closed in a clearly labeled bin 
and/or area of the storage unit  
Store pediatric and adult formulations 
separately, away from each other and 
other look- or sound-alike vaccines; e.g., 
HepA, Hib, HPV
Hepatitis B Vaccine Storage and Handling 
Vaccine storage label example
Available at www.cdc.gov/vaccines/hcp/admin/storage/guide/vaccine-storage-labels.pdf
Resources
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Information for Parents: 
Hepatitis B and the Vaccine 
(Shot) to Prevent It 
CDC accessed 4/8/2018 https://www.cdc.gov/vaccines/parents/diseases/child/hepB-basics-color.pdf
Hepatitis B Standing Order Templates 
Children and Adults 
Immunization Action Coalition access 4/8/2018 Children http://www.immunize.org/catg.d/p3076a.pdf Adult http://www.immunize.org/catg.d/p3076.pdf
Ask the Experts–Hepatitis B FAQs: 
www.immunize.org/askexperts/experts_hepb.asp 
CDC Viral Hepatitis–Hepatitis B Information: 
www.cdc.gov/hepatitis/hbv/index.htm 
CDC Hepatitis B Vaccination: 
www.cdc.gov/vaccines/vpd/hepb/index.html 
Hepatitis B and the Vaccine (Shot) to Prevent It–Information for 
Parents: www.cdc.gov/vaccines/parents/diseases/child/hepB-
basics-color.pdf 
Hepatitis B Facts–Testing and Vaccination: 
www.immunize.org/catg.d/p2110.pdf 
Hepatitis B and Health Care Personnel–FAQs: 
www.immunize.org/catg.d/p2109.pdf 
Infection Prevention during Blood Glucose Monitoring and 
Insulin Administration: www.cdc.gov/injectionsafety/blood-
glucose-monitoring.html 
Preexposure Evaluation for Health Care Personnel Previously 
Vaccinated with Complete ≥3-Dose HepB Vaccine Series Who 
Have Not Had Postvaccination Serologic Testing (Figure 3): 
www.cdc.gov/mmwr/volumes/67/rr/pdfs/rr6701-H.pdf
